BUPE2024

Do you need year-end CMEs/CPEs?

Registration: $299.00

Don't miss this important online resource.

Don’t miss your chance to earn quick and easy CME and CPE credits⁺ with BUPE2024 before the year ends! This premier virtual conference offers on-demand access to cutting-edge education on buprenorphine’s role in pain management, addiction treatment, and public health. Designed for busy healthcare professionals, BUPE2024 provides a convenient way to enhance your expertise while earning the credits you need—right from the comfort of your home or office. Act now to stay ahead in your field and complete your year-end credit requirements effortlessly. Register today and unlock valuable knowledge and career advancement!

As the field of medicine turns away from traditional strong opioids, the latest research and experts in pain management now point to buprenorphine as a front-line first-line opioid analgesic.

To present cutting-edge information on this growing alternative, Journal of Opioid Management (JOM) is pleased to present an online virtual conference and resource called, BUPE2024.COM filled with latest research and information on buprenorphine. This unique conference features a collection of presentations from experts in the field who are utilizing this in their practices and hospital systems. We thank them for their extensive efforts!

LEARN about the expanding role of buprenorphine in medicine and pain management from 14+ video sessions of cutting-edge topics!

This course meets the requirements for the DEA’s 8-hour training on opioid and other substance abuse!¹²

1 https://deadiversion.usdoj.gov/pubs/docs/MATE_Training_Letter_Final.pdf

2 https://wmpllc.org/ojs/index.php/jom/libraryFiles/downloadPublic/37

Presented by the Journal of Opioid Management®

Featured Presentations

Buprenorphine: Not Just Another Opioid

Understanding the World’s Most Interesting Opioid

Andrea Rubinstein, MD

Emerging Trends in Perioperative

Buprenorphine Management

Amanda L. Engle, PharmD, BCPS; Jacqueline Cleary, PharmD, BCACP; Amanda Winans, PharmD, BCPS, CACP

Buprenorphine: The Opioid that Cried ‘Partial Agonist’

Jeffrey J. Bettinger, PharmD; Jacqueline Cleary, PharmD, BCACP

Buprenorphine for Cancer Pain:

Results from a Systematic Review

Maria Silveira MD MA MPH; Victoria Powell MD

Conversion of CII Opioid Medications

to Buprenorphine in the Chronic Pain Population

Insights and Clinical Pearls

Amanda Zimmerman, PA-C

Partial Agonist, Full Barrier: A Case-Based Discussion

on Challenges with Buprenorphine

in Chronic Pain Management

Tonya S. Hershman, PharmD; BCPS, Michelle Park, MD

Buprenorphine for the Treatment of Pain

in Cancer Patients

Marcin Chwistek, MD, FAAHPM; Dylan Sherry, MD;

Leigh Kinczewski, CRNP

Impact of an Education Module on the Knowledge

and Attitudes of EM Physicians Towards Prescribing

Buprenorphine / Naloxone for Opioid Use Disorder

Amy Zosel, MD, MSCS; Jennifer Hernandez-Meier, PhD, MSW;

Julie Owen, MD, MBA

Buprenorphine: Opioid Agonist-Antagonist Benefits

for Opioid Resistant Pain Uncontrolled By Full-Agonist

Opioids during Hematopoietic Stem Cell Transplant

for Sickle Cell Disease

Mayuko Sakae, MD

Clinical Pharmacist with DEA License:

Efforts to Increase Access to Buprenorphine

in a Veteran Population

Shelley Stevens, PharmD, BCPS

Outpatient Cross-Titration to Buprenorphine

for Chronic Pain

Katherin Peperzak, MD

Buprenorphine Use in the Military Health System (MHS)

Nicole Cornish, PharmD

The “Micro”cosm: Magnifying the Nuance of Low Dose Buprenorphine Inductions

Tanya Uritsky. PharmD, BCPP, Emily Casey, PharmD

“My addiction doesn’t define me:”

Healing from the stigma of addiction for mothers

with opioid use disorder

Christine Bakos-Block, PhD, LCSW-S; Francine Vega, MS, CCC-SLP;

A. Sarah Cohen, MS; Tiffany Champagne-Langabeer, PhD

Plus, 11 encore presentations from BUPE2021!

Registration: $299.00

Don't miss this important online resource.

Course Directors

Mellar P. Davis, MD, FCCP, FAAHPM

Mary Lynn McPherson, PharmD, PhD, BCPS, FAAHPM

Learning Objectives

At the end of this educational activity, participants should be able to:

Describe the therapeutic benefits of buprenorphine and highlight indications for its use in acute, chronic, and cancer pain.
Explain interactions of buprenorphine with other opioids.
Explain the appropriate application of buprenorphine in pain patients and those with co-morbid substance use disorder.
Explain the concepts and practice of micro-dosing, rotation, and titration.
Recognize the legal and regulatory implications of prescribing opioids that arise when treating individuals in pain.
Explain the basic pharmacology of buprenorphine and utilize and promote evidence-based approaches for clinical treatment.
Describe the various delivery methods for buprenorphine in the management of pain.

Accreditation

In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and Weston Medical Publishing.

Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians:

Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 9.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PharmD/Pharmacist:

This activity is approved for 9.25 CPE credit(s) under the ACPE universal activity number UAN JA0000185-9999-24-033-H01-P. The activity is available for credit claiming through 60 days after your participation.

Background: In 2019 the Department of Health and Human Services pain management guidelines recommended buprenorphine, a Schedule III opioid, before considering schedule II opioids in managing moderate to severe pain. As the paradigm surrounding opioid prescription continues to shift, sign up and take advantage of the great presentations at BUPE2024.COM.

Special Supplement: Registrants will also receive a digital copy of Journal of Opioid Management's special issue “Buprenorphine: Clinical and Public Policy Implications".

⁺Once you are registered and logged into the website, you can click on the "info" then "CME/CPE Information". In the "Claim Your Credit" section, you will see a link and course code needed to take the Post Test. If you need credits for 2024, please make sure you complete the post test before 11:59pm EST on 12/31/24. BUPE2024 will be available through August 2025.

Journal of Opioid Management | 781-899-2702 | 470 Boston Post Road, Suite 301

Weston, MA 02493 USA | www.opioidmanagementjournal.com

Journal of Opioid Management is a registered trademark of Weston Medical Publishing, LLC, BUPE2024, BUPE2021 and Buprenorphine in Medicine: Clinical and Public Policy Implications are trademarks of Weston Medical Publishing, LLC. Copyright 2024, Weston Medical Publishing, LLC. All Rights Reserved.